Insulet Corporation (PODD)
NASDAQ: PODD · Real-Time Price · USD
304.49
-11.43 (-3.62%)
At close: Dec 5, 2025, 4:00 PM EST
304.20
-0.29 (-0.10%)
After-hours: Dec 5, 2025, 7:49 PM EST
Insulet Revenue
Insulet had revenue of $521.70M in the quarter ending September 30, 2025, with 40.02% growth. This brings the company's revenue in the last twelve months to $1.85B, up 32.55% year-over-year. In the year 2024, Insulet had annual revenue of $1.48B with 21.28% growth.
Revenue (ttm)
$1.85B
Revenue Growth
+32.55%
P/S Ratio
8.49
Revenue / Employee
$646,615
Employees
3,900
Market Cap
21.42B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.48B | 260.40M | 21.28% |
| Dec 31, 2023 | 1.22B | 168.00M | 15.92% |
| Dec 31, 2022 | 1.06B | 14.80M | 1.42% |
| Dec 31, 2021 | 1.04B | 136.20M | 15.06% |
| Dec 31, 2020 | 904.40M | 166.20M | 22.51% |
| Dec 31, 2019 | 738.20M | 174.40M | 30.93% |
| Dec 31, 2018 | 563.80M | 100.00M | 21.56% |
| Dec 31, 2017 | 463.80M | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | 263.89M | 32.57M | 14.08% |
| Dec 31, 2014 | 231.32M | -15.76M | -6.38% |
| Dec 31, 2013 | 247.08M | 35.72M | 16.90% |
| Dec 31, 2012 | 211.37M | 59.11M | 38.83% |
| Dec 31, 2011 | 152.26M | 55.29M | 57.02% |
| Dec 31, 2010 | 96.97M | 30.93M | 46.85% |
| Dec 31, 2009 | 66.03M | 29.97M | 83.12% |
| Dec 31, 2008 | 36.06M | 22.69M | 169.66% |
| Dec 31, 2007 | 13.37M | 9.71M | 265.06% |
| Dec 31, 2006 | 3.66M | 3.61M | 7,226.00% |
| Dec 31, 2005 | 50.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
PODD News
- 2 days ago - Insulet Announces FDA 510(k) Clearance of Omnipod® 5 Algorithm Enhancements that Redefine Insulin Delivery and Simplify the Pod Experience - Business Wire
- 10 days ago - Artisan International Small-Mid Fund Q3 2025 Contrarianism Pays Off - Seeking Alpha
- 16 days ago - Insulet Corporation (PODD) Analyst/Investor Day Transcript - Seeking Alpha
- 16 days ago - Insulet Outlines Long-Term Strategy to Drive Growth and Value Creation at 2025 Investor Day - Business Wire
- 24 days ago - PODD Vs. Intuitive Surgical: This Underdog Might Just Win - Forbes
- 4 weeks ago - Insulet Corporation (PODD) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Insulet tops quarterly estimates on demand for wearable insulin pumps - Reuters
- 4 weeks ago - Insulet Reports Third Quarter 2025 Results - Business Wire